Cove Private Wealth LLC Grows Holdings in Becton, Dickinson and Company $BDX

Cove Private Wealth LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 11.2% in the second quarter, Holdings Channel reports. The institutional investor owned 3,134 shares of the medical instruments supplier’s stock after purchasing an additional 316 shares during the period. Cove Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $540,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $27,000. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $29,000. Cornerstone Planning Group LLC increased its stake in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $184.59 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market capitalization of $52.91 billion, a price-to-earnings ratio of 33.20, a PEG ratio of 1.46 and a beta of 0.27. The company’s 50-day moving average is $188.27 and its two-hundred day moving average is $188.97. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company’s revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.3%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Insider Activity

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock worth $551,536 over the last quarter. 0.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on BDX. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada started coverage on shares of Becton, Dickinson and Company in a research note on Thursday. They set a “sector perform” rating and a $211.00 target price for the company. Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $213.09.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.